- Home
- News
- canada british columbia
- immune memory
Immune Memory Articles & Analysis
4 news found
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infection Immune memory against conserved nucleoprotein may provide an added advantage over spike-only responses Memory T and B cells persisted for at least 6 months post vaccination Data suggest COVAXIN™ (BBV152) may provide protection against current and future ...
Oslo, April 22, 2020 – NEC OncoImmunity AS today announced analysis results from efforts using AI prediction platforms to design blueprints for SARS-CoV-2 vaccines that can drive potent T-cell responses in the majority of the global population. This initiative by the scientific teams within the NEC Group to help combat outbreaks of COVID-19 and support international vaccine development ...
T3 Pharmaceuticals (“T3 Pharma”), a biotech company with a focus on immuno-oncology, today announced it has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models. The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists ...